[1]

Spinelli JB, Haigis MC. 2018. The multifaceted contributions of mitochondria to cellular metabolism. Nature Cell Biology 20:745−754

doi: 10.1038/s41556-018-0124-1
[2]

Machado ND, Heather LC, Harris AL, Higgins GS. 2023. Targeting mitochondrial oxidative phosphorylation: lessons, advantages, and opportunities. British Journal of Cancer 129:897−899

doi: 10.1038/s41416-023-02394-9
[3]

Mitchell P. 1961. Coupling of phosphorylation to electron and hydrogen transfer by a chemi-osmotic type of mechanism. Nature 191:144−148

doi: 10.1038/191144a0
[4]

Martínez-Reyes I, Chandel NS. 2021. Cancer metabolism: looking forward. Nature Reviews Cancer 21:669−680

doi: 10.1038/s41568-021-00378-6
[5]

Degli Esposti M. 1998. Inhibitors of NADH-ubiquinone reductase: an overview. Biochimica et Biophysica Acta (BBA) - Bioenergetics 1364:222−235

doi: 10.1016/S0005-2728(98)00029-2
[6]

Trumpower BL. 1990. Cytochrome bc1 complexes of microorganisms. Microbiological Reviews 54:101−129

doi: 10.1128/mr.54.2.101-129.1990
[7]

Vercellino I, Sazanov LA. 2022. The assembly, regulation and function of the mitochondrial respiratory chain. Nature Reviews Molecular Cell Biology 23:141−161

doi: 10.1038/s41580-021-00415-0
[8]

Murphy MP. 2009. How mitochondria produce reactive oxygen species. The Biochemical Journal 417:1−13

doi: 10.1042/bj20081386
[9]

Scialò F, Fernández-Ayala DJ, Sanz A. 2017. Role of mitochondrial reverse electron transport in ROS signaling: potential roles in health and disease. Frontiers in Physiology 8:428

doi: 10.3389/fphys.2017.00428
[10]

Andries K, Verhasselt P, Guillemont J, Göhlmann HWH, Neefs JM, et al. 2005. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307:223−227

doi: 10.1126/science.1106753
[11]

Koul A, Vranckx L, Dhar N, Göhlmann HWH, Özdemir E, et al. 2014. Delayed bactericidal response of Mycobacterium tuberculosis to bedaquiline involves remodelling of bacterial metabolism. Nature Communications 5:3369

doi: 10.1038/ncomms4369
[12]

Guglielmetti L, Khan U, Velásquez GE, Gouillou M, Abubakirov A, et al. 2025. Oral regimens for rifampin-resistant, fluoroquinolone-susceptible tuberculosis. The New England Journal of Medicine 392:468−482

doi: 10.1056/NEJMoa2400327
[13]

Porporato PE, Filigheddu N, Pedro JMB, Kroemer G, Galluzzi L. 2018. Mitochondrial metabolism and cancer. Cell Research 28:265−280

doi: 10.1038/cr.2017.155
[14]

Gowans FA, Thach DQ, Zhu Z, Wang Y, Altamirano Poblano BE, et al. 2024. Ophiobolin a covalently targets mitochondrial complex IV leading to metabolic collapse in cancer cells. ACS Chemical Biology 19:1260−1270

doi: 10.1021/acschembio.4c00064
[15]

Bridges HR, Blaza JN, Yin Z, Chung I, Pollak MN, et al. 2023. Structural basis of mammalian respiratory complex I inhibition by medicinal biguanides. Science 379:351−357

doi: 10.1126/science.ade3332
[16]

Owen MR, Doran E, Halestrap AP. 2000. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. The Biochemical Journal 348:607−614

doi: 10.1042/bj3480607
[17]

Foretz M, Guigas B, Viollet B. 2019. Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus. Nature Reviews Endocrinology 15:569−589

doi: 10.1038/s41574-019-0242-2
[18]

Rena G, Hardie DG, Pearson ER. 2017. The mechanisms of action of metformin. Diabetologia 60:1577−1585

doi: 10.1007/s00125-017-4342-z
[19]

Reczek CR, Chakrabarty RP, D'Alessandro KB, Sebo ZL, Grant RA, et al. 2024. Metformin targets mitochondrial complex I to lower blood glucose levels. Science Advances 10:eads5466

doi: 10.1126/sciadv.ads5466
[20]

Cheng Y. 2015. Single-particle cryo-EM at crystallographic resolution. Cell 161:450−457

doi: 10.1016/j.cell.2015.03.049
[21]

Kühlbrandt W. 2014. The resolution revolution. Science 343:1443−1444

doi: 10.1126/science.1251652
[22]

Xia D, Yu CA, Kim H, Xia JZ, Kachurin AM, et al. 1997. Crystal structure of the cytochrome bc1 complex from bovine heart mitochondria. Science 277:60−66

doi: 10.1126/science.277.5322.60
[23]

Zhu J, Vinothkumar KR, Hirst J. 2016. Structure of mammalian respiratory complex I. Nature 536:354−358

doi: 10.1038/nature19095
[24]

Hahn A, Parey K, Bublitz M, Mills DJ, Zickermann V, et al. 2016. Structure of a complete ATP synthase dimer reveals the molecular basis of inner mitochondrial membrane morphology. Molecular Cell 63:445−456

doi: 10.1016/j.molcel.2016.05.037
[25]

Gu J, Wu M, Guo R, Yan K, Lei J, et al. 2016. The architecture of the mammalian respirasome. Nature 537:639−643

doi: 10.1038/nature19359
[26]

Zheng W, Chai P, Zhu J, Zhang K. 2024. High-resolution in situ structures of mammalian respiratory supercomplexes. Nature 631:232−239

doi: 10.1038/s41586-024-07488-9
[27]

Letts JA, Sazanov LA. 2017. Clarifying the supercomplex: the higher-order organization of the mitochondrial electron transport chain. Nature Structural & Molecular Biology 24:800−808

doi: 10.1038/nsmb.3460
[28]

Kampjut D, Sazanov LA. 2020. The coupling mechanism of mammalian respiratory complex I. Science 370:eabc4209

doi: 10.1126/science.abc4209
[29]

MacLean AE, Shikha S, Ferreira Silva M, Gramelspacher MJ, Nilsen A, et al. 2025. Structure, assembly and inhibition of the Toxoplasma gondii respiratory chain supercomplex. Nature Structural & Molecular Biology 32:1424−1433

doi: 10.1038/s41594-025-01531-7
[30]

Mühleip A, Flygaard RK, Baradaran R, Haapanen O, Gruhl T, et al. 2023. Structural basis of mitochondrial membrane bending by the I-II-III2-IV2 supercomplex. Nature 615:934−938

doi: 10.1038/s41586-023-05817-y
[31]

Wallace DC. 2018. Mitochondrial genetic medicine. Nature Genetics 50:1642−1649

doi: 10.1038/s41588-018-0264-z
[32]

Hoogstraten CA, Lyon JJ, Smeitink JAM, Russel FGM, Schirris TJJ. 2023. Time to change: a systems pharmacology approach to disentangle mechanisms of drug-induced mitochondrial toxicity. Pharmacological Reviews 75:463−486

doi: 10.1124/pharmrev.122.000568
[33]

Li J, Yang S, Wu Y, Wang R, Liu Y, et al. 2024. Alternative oxidase: from molecule and function to future inhibitors. ACS Omega 9:12478−12499

doi: 10.1021/acsomega.3c09339
[34]

Saha P, Das S, Indurthi HK, Kumar R, Roy A, et al. 2024. Cytochrome bd oxidase: an emerging anti-tubercular drug target. RSC Medicinal Chemistry 15:769−787

doi: 10.1039/d3md00587a
[35]

Han S, Lee M, Shin Y, Giovanni R, Chakrabarty RP, et al. 2023. Mitochondrial integrated stress response controls lung epithelial cell fate. Nature 620:890−897

doi: 10.1038/s41586-023-06423-8
[36]

Marchi S, Guilbaud E, Tait SWG, Yamazaki T, Galluzzi L. 2023. Mitochondrial control of inflammation. Nature Reviews Immunology 23:159−173

doi: 10.1038/s41577-022-00760-x
[37]

Chandel NS. 2015. Evolution of mitochondria as signaling organelles. Cell Metabolism 22:204−206

doi: 10.1016/j.cmet.2015.05.013
[38]

Hirst J. 2013. Mitochondrial complex I. Annual Review of Biochemistry 82:551−575

doi: 10.1146/annurev-biochem-070511-103700
[39]

Anand P, Akhter Y. 2022. A review on enzyme complexes of electron transport chain from Mycobacterium tuberculosis as promising drug targets. International Journal of Biological Macromolecules 212:474−494

doi: 10.1016/j.ijbiomac.2022.05.124
[40]

Koul A, Arnoult E, Lounis N, Guillemont J, Andries K. 2011. The challenge of new drug discovery for tuberculosis. Nature 469:483−490

doi: 10.1038/nature09657
[41]

Steinberg GR, Carling D. 2019. AMP-activated protein kinase: the current landscape for drug development. Nature Reviews Drug Discovery 18:527−551

doi: 10.1038/s41573-019-0019-2
[42]

Vyas S, Zaganjor E, Haigis MC. 2016. Mitochondria and cancer. Cell 166:555−566

doi: 10.1016/j.cell.2016.07.002
[43]

Nolfi-Donegan D, Braganza A, Shiva S. 2020. Mitochondrial electron transport chain: oxidative phosphorylation, oxidant production, and methods of measurement. Redox Biology 37:101674

doi: 10.1016/j.redox.2020.101674
[44]

Trumpower BL. 1990. The protonmotive Q cycle. Energy transduction by coupling of proton translocation to electron transfer by the cytochrome bc1 complex. The Journal of Biological Chemistry 265:11409−11412

doi: 10.1016/s0021-9258(19)38410-8
[45]

Berry EA, Huang LS. 2003. Observations concerning the quinol oxidation site of the cytochrome bc1 complex. FEBS Letters 555:13−20

doi: 10.1016/S0014-5793(03)01099-8
[46]

Symersky J, Osowski D, Walters DE, Mueller DM. 2012. Oligomycin frames a common drug-binding site in the ATP synthase. Proceedings of the National Academy of Sciences of the United States of America 109:13961−13965

doi: 10.1073/pnas.1207912109
[47]

Walker JE. 1998. ATP synthesis by rotary catalysis (Nobel lecture). Angewandte Chemie International Edition 37:2308−2319

doi: 10.1002/(sici)1521-3773(19980918)37:172308::aid-anie2308>3.0.co;2-w
[48]

Trachootham D, Alexandre J, Huang P. 2009. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nature Reviews Drug Discovery 8:579−591

doi: 10.1038/nrd2803
[49]

He Z, Teng F, Yang Y, Guo R, Wu M, et al. 2026. Hydrophilic metformin and hydrophobic biguanides inhibit mitochondrial complex I by distinct mechanisms. Nature Structural & Molecular Biology 33:100−111

doi: 10.1038/s41594-025-01710-6
[50]

Hardie DG. 2011. AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes & Development 25:1895−1908

doi: 10.1101/gad.17420111
[51]

Fiedorczuk K, Letts JA, Degliesposti G, Kaszuba K, Skehel M, et al. 2016. Atomic structure of the entire mammalian mitochondrial complex I. Nature 538:406−410

doi: 10.1038/nature19794
[52]

Hunte C, Koepke J, Lange C, Roßmanith T, Michel H. 2000. Structure at 2.3 Å resolution of the cytochrome bc1 complex from the yeast Saccharomyces cerevisiae co-crystallized with an antibody Fv fragment. Structure 8:669−684

doi: 10.1016/S0969-2126(00)00152-0
[53]

Preiss L, Langer JD, Yildiz Ö, Eckhardt-Strelau L, Guillemont JEG, et al. 2015. Structure of the mycobacterial ATP synthase Fo rotor ring in complex with the anti-TB drug bedaquiline. Science Advances 1:e1500106

doi: 10.1126/sciadv.1500106
[54]

Cook GM, Hards K, Vilchèze C, Hartman T, Berney M. 2014. Energetics of respiration and oxidative phosphorylation in mycobacteria. Microbiology Spectrum 2:MGM2-0015-2013

doi: 10.1128/microbiolspec.mgm2-0015-2013
[55]

Haagsma AC, Abdillahi-Ibrahim R, Wagner MJ, Krab K, Vergauwen K, et al. 2009. Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue. Antimicrobial Agents and Chemotherapy 53:1290−1292

doi: 10.1128/AAC.01393-08
[56]

Imran M, Abida, Alotaibi NM, Thabet HK, Alruwaili JA, et al. 2023. QcrB inhibition as a potential approach for the treatment of tuberculosis: a review of recent developments, patents, and future directions. Journal of Infection and Public Health 16:928−937

doi: 10.1016/j.jiph.2023.04.011
[57]

de Jager VR, Dawson R, van Niekerk C, Hutchings J, Kim J, et al. 2020. Telacebec (Q203), a new antituberculosis agent. The New England Journal of Medicine 382:1280−1281

doi: 10.1056/NEJMc1913327
[58]

Fisher N, Meunier B. 2008. Molecular basis of resistance to cytochrome bc1 inhibitors. FEMS Yeast Research 8:183−192

doi: 10.1111/j.1567-1364.2007.00328.x
[59]

Esser L, Quinn B, Li YF, Zhang M, Elberry M, et al. 2004. Crystallographic studies of quinol oxidation site inhibitors: a modified classification of inhibitors for the cytochrome bc1 complex. Journal of Molecular Biology 341:281−302

doi: 10.1016/j.jmb.2004.05.065
[60]

Molina JR, Sun Y, Protopopova M, Gera S, Bandi M, et al. 2018. An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nature Medicine 24:1036−1046

doi: 10.1038/s41591-018-0052-4
[61]

Janku F, Beom SH, Moon YW, Kim TW, Shin YG, et al. 2022. First-in-human study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors. Investigational New Drugs 40:1001−1010

doi: 10.1007/s10637-022-01277-9
[62]

Luna Yolba R, Visentin V, Hervé C, Chiche J, Ricci JE, et al. 2021. EVT-701 is a novel selective and safe mitochondrial complex 1 inhibitor with potent anti-tumor activity in models of solid cancers. Pharmacology Research & Perspectives 9:e00854

doi: 10.1002/prp2.854
[63]

Ellinghaus P, Heisler I, Unterschemmann K, Haerter M, Beck H, et al. 2013. BAY 87-2243, a highly potent and selective inhibitor of hypoxia-induced gene activation has antitumor activities by inhibition of mitochondrial complex I. Cancer Medicine 2:611−624

doi: 10.1002/cam4.112
[64]

Chidley C, Trauger SA, Birsoy K, O'Shea EK. 2016. The anticancer natural product ophiobolin A induces cytotoxicity by covalent modification of phosphatidylethanolamine. eLife 5:e14601

doi: 10.7554/eLife.14601